T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph plus Acute Lymphoblastic Leukemia

被引：0

作者：

Leonard, Jessica ^{[1
]}

Kosaka, Yoko ^{[2
]}

Malla, Pavani ^{[3
]}

Hayes-Lattin, Brandon ^{[4
]}

Lamble, Adam J. ^{[5
]}

Druker, Brian J. ^{[1
]}

Tyner, Jeffrey W. ^{[6
]}

Chang, Bill H. ^{[3
]}

Lind, Evan F. ^{[7
]}

机构：

[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[2] Oregon Hlth & Sci Univ, Microbiol & Immunol, Portland, OR 97201 USA

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[5] Seattle Childrens Hosp, Hematol Oncol, Seattle, WA USA

[6] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA

[7] Oregon Hlth & Sci Univ, Microbiol & Immunol, Portland, OR 97201 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-119301

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2694

引用

页数：4

共 50 条

[31] Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia
Buie, Larry W.
Pecoraro, Joshua J.
Horvat, Troy Z.
Daley, Ryan J.
ANNALS OF PHARMACOTHERAPY, 2015, 49 (09) : 1057 - 1067
[32] Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements
Tanasi, Ilaria
Ba, Ibrahima
Sirvent, Nicolas
Braun, Thorsten
Cuccuini, Wendy
Ballerini, Paola
Duployez, Nicolas
Tanguy-Schmidt, Aline
Tamburini, Jerome
Maury, Sebastien
Dore, Eric
Himberlin, Chantal
Duclos, Cedric
Chevallier, Patrice
Rousselot, Philippe
Bonifacio, Massimiliano
Cave, Helene
Baruchel, Andre
Dombret, Herve
Soulier, Jean
Landman-Parker, Judith
Boissel, Nicolas
Clappier, Emmanuelle
BLOOD, 2019, 134 (16) : 1351 - 1355
[33] Blinatumomab plus Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience
Couturier, Marie-Anne
Thomas, Xavier
Huguet, Francoise
Berthon, Celine
Simand, Celestine
Hicheri, Yosr
Hunault, Mathilde
Chevallier, Patrice
BLOOD, 2018, 132
[34] ABL1 and Cofilin1 promote T-cell acute lymphoblastic leukemia cell migration
Luo, Jixian
Zheng, Huiguang
Wang, Sen
Li, Dingyun
Ma, Wenli
Wang, Lan
Crabbe, M. James C.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2021, 53 (10) : 1321 - 1332
[35] Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency
Ramdeny, Sandheeah
Chaudhary, Asima
Worth, Austen
Ghorashian, Sara
Slatter, Mary
Lum, Su Han
Vora, Ajay
BLOOD ADVANCES, 2021, 5 (08) : 2153 - 2155
[36] Choline Kinase a Is Required for Alkylating Agent Resistance in T-Cell Acute Lymphoblastic Leukemia
Barthe, Anais
Bodaar, Kimberly
Issaian, Aaron
Aboagye, Eric
D'Alessandro, Angelo
Gutierrez, Alejandro
BLOOD, 2022, 140 : 2258 - 2258
[37] The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph plus Acute Lymphoblastic Leukemia
Gurman, Gunhan
Merter, Mustafa
Ataca, Pinar
Ozen, Mehmet
Atesagaoglu, Berna
Gunduz, Mehmet
Pekcan, Gultekin
Sahin, Ugur
Toprak, Selami Kocak
Topcuoglu, Pervin
Ozcan, Muhit
Ilhan, Osman
Atilla, Erden
BLOOD, 2014, 124 (21)
[38] Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph plus Acute Lymphoblastic Leukemia
Minhajuddin, Mohd
Winters, Amanda C.
Schwartz, Marc
Pollyea, Daniel A.
Jordan, Craig T.
BLOOD, 2022, 140 : 5986 - 5987
[39] Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia
Sergio, Ilaria
Varricchio, Claudia
Squillante, Federica
Aeo, Noemi Martina Cantale
Campese, Antonio Francesco
Felli, Maria Pia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
[40] Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Lulla, Premal D.
Mamonkin, Maksim
Brenner, Malcolm K.
CANCER JOURNAL, 2019, 25 (03): : 199 - 207

← 1 2 3 4 5 →